ASCO 2026 | ASCENT-07: SG in patients with HER2 IHC0 HR+/HER2- breast cancer
Yeon Hee Park, MD, Samsung Medical Center, Seoul, South Korea, presents an exploratory subgroup analysis from ASCENT-07 (NCT05840211), evaluating sacituzumab govitecan (SG) versus chemotherapy in patients with HR-positive, HER2-negative metastatic breast cancer (mBC) with HER2 IHC0 expression status. Results showed numerical trends toward improved progression-free survival and a manageable safety profile with SG, supporting further investigation of this agent in patients with HER2 IHC0 mBC eligible for first chemotherapy. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
It’s really different for the ASCENT-07 study, which is ER-positive HER2-negative breast cancer. Actually, the first-line after endocrine treatment, first-line ADC versus physician’s choice treatment of cytotoxic chemotherapy was a backbone. And they showed a similar outcome compared to the SD versus physician’s choice chemotherapy, which does not show any difference in terms of statistical analysis and purpose...
It’s really different for the ASCENT-07 study, which is ER-positive HER2-negative breast cancer. Actually, the first-line after endocrine treatment, first-line ADC versus physician’s choice treatment of cytotoxic chemotherapy was a backbone. And they showed a similar outcome compared to the SD versus physician’s choice chemotherapy, which does not show any difference in terms of statistical analysis and purpose. So at this point, usually, high-to-low and high-to-ultra-low population can be treated with TDxd, but what about the IHC0 populations at this point? The extent of O7 subgroup analysis according to the IHC0 population did not show any significant difference, just numerical superiority for SG were found, 9.3 months versus 8.1 months. But anyway, the overall survival showed a little bit of a trend, but still immature data. So we need a long-term follow-up, digging into the IHC zero patient population.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
